Enhanced expression of β cell Cav3.1 channels impairs insulin release and glucose homeostasis

Jia Yu1,2, Yue Shi1, Kaixuan Zhao3, Guang Yang4, Lina Yu5, Yuxin Li5, Eva-Marie Andersson5, Carina Ämmälä4, Shao-Nian Yang4,5,6,7, and Per-Olof Berggren5,6,8,9

*The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, SE-171 76 Stockholm, Sweden; †Institute of Pharmacology, Jilin Academy of Traditional Chinese Medicine, Changchun 130021, China; ‡National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China; §Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 38 Mölndal, Gothenburg, Sweden; and †Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, China

Edited by Bruce M. Spiegelman, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, and approved November 26, 2019 (received for review May 20, 2019)

Multiple types of voltage-gated calcium (Cav) channels, including Cav3.1, operate in the pancreatic β cell mediating Ca2+ influx in response to membrane depolarization evoked by increased blood glucose (1–7). Ca2+ influx through all types of Cav channels and Ca2+ mobilization mediated by intracellular Ca2+ release channels in the β cell regulate glucose-stimulated insulin secretion (1, 5–8). In this context, β cell Cav3.1 channels serve as a predominant player compared to other types of β cell Cav channels due to an optimal elevation in cytosolic free Ca2+ concentration ([Ca2+]i) within exocytotic sites (1, 5–7). This optically elevated [Ca2+]i allosterically initiates direct interactions between exocytotic proteins such as VAMP-2, synaptotagmins III and VII in the insulin granule membrane, and syntaxin 1A and SNAP-25 in the plasma membrane (5–7, 9). These interactions trigger fusion of insulin granules with the plasma membrane to form fusion pores for insulin cargo release in the first phase of glucose stimulation (5–7, 9). It is most likely that Ca2+ influx mediated by other types of β cell Cav channels mildly raises [Ca2+]i in regions which do not overlap well with exocytotic sites (5–7). This appears to facilitate trafficking of insulin granules to the readily releasable pool to be involved in late-phase but not early-phase glucose-stimulated insulin secretion (5–7). Although it has been suggested that physiological Ca2+ influx through Cav3 channels participates in glucose-stimulated insulin secretion, the underlying mechanisms are not known (6, 7, 10, 11).

The Cav3.1 channel is absent in healthy mouse β cells, whereas it resides in healthy rat and human β cells to conduct T-type Ca2+ currents, accounting for only a minor proportion of total Cav currents (6, 7, 10, 12, 13). T-type Ca2+ currents appear in diabetic mouse β cells and are significantly increased in diabetic rat β cells (14, 15). Despite little understanding of the physiological role of the Cav3.1 channel in the β cell, there is a possibility that this Cav3.1 channel affects expression of exocytotic proteins under diabetic conditions (6, 7). Ca2+-dependent protein phosphatase calcineurin (CaN) undergoes activation when [Ca2+]i increases (16). Activated CaN may suppress the expression of exocytotic calcium channel | diabetes | exocytotic proteins | forkhead box O transcription factor | insulin secretion

Significance

We reveal that increased expression of Cav3.1 channels in rat islets selectively impairs first-phase glucose-stimulated insulin secretion. This deterioration is recapitulated in human islets. Its causal role in diabetes development is clearly manifested in an in vivo diabetic model. Mechanistically, this is due to reduction of phosphorylated FoxO1 in the cytoplasm, elevated FoxO1 nuclear retention, and decreased syntaxin 1A, SNAP-25, and synaptotagmin III. These effects were prevented by inhibiting Cav3.1 channels or the Ca2+-dependent phosphatase calcineurin. Enhanced expression of β cell Cav3.1 channels therefore impairs insulin release and glucose homeostasis by means of initial excessive Ca2+ influx, subsequent activation of calcineurin, consequent dephosphorylation and nuclear retention of FoxO1, and eventual FoxO1-mediated down-regulation of β cell exocytotic proteins. The present work thus suggests an elevated expression of Cav3.1 channels plays a significant role in diabetes pathogenesis.

Author contributions: J.Y., Y.S., S.-N.Y., and P.-O.B. designed research; J.Y., Y.S., K.Z., G.Y., L.Y., Y.L., and S.-N.Y. performed research; E.-M.A. and C.A. contributed new reagents/analytic tools; J.Y., Y.S., K.Z., G.Y., L.Y., and S.-N.Y. analyzed data; and J.Y., S.-N.Y., and P.-O.B. wrote the paper.

Competing interest statement: P.-O.B. is the founder and CEO of the biotech company BioCrine AB. S.-N.Y. is a consultant for BioCrine AB.

This article is a PNAS Direct Submission. This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

1J.Y. and Y.S. contributed equally to this work.
To whom correspondence may be addressed. Email: Jia.Yu@ki.se, Shao-Nian.Yang@ki.se, or Per-Olof.Berggren@ki.se.
3S.-N.Y. and P.-O.B. contributed equally to this work.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1908691117/-/DCSupplemental.

First published December 23, 2019.
proteins through dephosphorylation of FoxO1 (17–19). Systemic administration of CaV3 channel blockers significantly ameliorates hyperglycemia in diabetic mice (20). However, the causal role and transcriptomic impact of a pathological elevation of β cell CaV3.1 channels in the development of diabetes is not known. We hypothesized that excessive Ca2+ influx through up-regulated CaV3.1 channels drives β cell dedifferentiation by constitutively hyper-activating CaN and downstream FoxO1 signaling. This is likely to result in impaired expression of β cell exocytotic proteins, disturbed insulin secretion, aberrant glucose homeostasis, and consequent diabetes. Our results verify that the hypothesized signaling pathway indeed operates in β cells up-expressing CaV3.1 channels, suggesting their important role in the pathogenesis of diabetes. This also means that CaV3.1 channels may serve as potential druggable targets in the treatment of diabetes.

Results and Discussion

Ad-EGFP-CaV3.1 Efficiently Transduces COS-7 and Rat Islet Cells, and Expressed EGFP-CaV3.1 Conducts Typical T-Type Ca2+ Currents. Recombinant adenovirus vectors have been verified to efficiently transduce islets (21). To elevate CaV3.1 channel expression in rat islets, we constructed recombinant adenoviruses carrying either enhanced green fluorescent protein (Ad-EGFP) or the EGFP-CaV3.1 subunit (Ad-EGFP-CaV3.1) and characterized them in COS-7 cells. Ad-EGFP (SI Appendix, Fig. S1 A, Top) and Ad-EGFP-CaV3.1 (SI Appendix, Fig. S1 A, Bottom) were efficiently expressed in COS-7 cells. Ad-EGFP-CaV3.1-positive cells displayed typical T-type Ca2+ currents characterized by tiny unitary conductance and fast inactivation (SI Appendix, Fig. S1 B, Right), whereas Ad-EGFP-positive cells showed no Ca2+ currents (SI Appendix, Fig. S1 B, Left). Furthermore, the former cells expressed genuine whole-cell T-type Ca2+ currents, which were transiently activated at more negative membrane potentials (SI Appendix, Fig. S1C, third and fourth panels), but the latter cells did not (SI Appendix, Fig. S1C, second panel). The effective expression and adequate functionality of Ad-EGFP-CaV3.1 in COS-7 cells offer a promising basis for elevation of CaV3.1 channels in rat islets.

We characterized expression and functionality of Ad-EGFP-CaV3.1 in dispersed rat islet cells using the same experimental approaches as employed in the above experiments. We observed that both Ad-EGFP-infected (SI Appendix, Fig. S2, Top) and Ad-EGFP-CaV3.1-infected islet cells (SI Appendix, Fig. S2, Bottom) emitted intense EGFP fluorescence. This substantiates that these recombinant adenoviral vectors can effectively express the EGFP and CaV3.1 genes in these cells. We also visualized 2 inward current components, peaking at about −45 and −5 mV, in control cells and cells transduced with Ad-EGFP- or Ad-EGFP-CaV3.1 (Fig. 1 A). The first component, i.e., low CaV currents, was significantly greater in Ad-EGFP-CaV3.1-treated cells than in control cells or cells infected with Ad-EGFP (Fig. 1 A and B). However, there was no obvious difference in the second component, namely, high CaV currents, between these 3 types of cells (Fig. 1 A and B). The data reveal that Ad-EGFP-CaV3.1 can satisfactorily transduce dispersed rat islet cells and compel these cells to additionally express functional CaV3.1 channels, thereby enhancing T-type Ca2+ currents.

It should be pointed out that we rarely visualized EGFP fluorescence in the plasma membrane of EGFP-CaV3.1-positive COS-7 (SI Appendix, Fig. S1A) and islet cells (SI Appendix, Fig. S2). Nevertheless, we could exclusively detect whole-cell T-type Ca2+ currents in these cells. This is due to the fact that a limited number of EGFP-CaV3.1 channels scatter throughout the plasma membrane and have a low probability of appearing in the tiny proportion of the plasma membrane in the focal plane of the confocal microscope.

Fig. 1. Effects of Ad-EGFP-CaV3.1 transduction on whole-cell Ca2+ currents in dispersed islet cells and on glucose-stimulated insulin secretion and [Ca2+]i in islets. (A) Sample whole-cell Ca2+ current traces from a control rat islet cell and a rat islet cell transduced with Ad-EGFP or Ad-EGFP-CaV3.1. (B) Average Ca2+ current density-voltage relationships in control (n = 13), Ad-EGFP (n = 11), and Ad-EGFP-CaV3.1 (n = 12) groups. **P < 0.01 vs. control and Ad-EGFP. (C and D) Dynamic insulin secretion from control, Ad-EGFP-transduced, and Ad-EGFP-CaV3.1-transduced rat (C) and human (D) islets perfused with 3 mM glucose (3G) followed by 16.7 mM glucose (16.7G). **P < 0.01 and *P < 0.05 vs. control and Ad-EGFP. Control rat islets (n = 13), Ad-EGFP-transduced rat islets (n = 10), Ad-EGFP-CaV3.1-transduced rat islets (n = 10), Ad-EGFP-transduced human islets (n = 6), and Ad-EGFP-CaV3.1-transduced human islets (n = 6). (E) Sample [Ca2+]i traces registered in Ad-EGFP- and Ad-EGFP-CaV3.1-transduced rat (Upper) and human (Lower) islets following perfusion with 3 mM (3G) and 16.7 mM glucose (16.7G) as well as 25 mM KCl (25K). (F) Quantitative analysis of average fura-2 F340/F380 ratios during exposure to 3 mM glucose and stimulation with 16.7 mM glucose and peak fura-2 F340/F380 ratios in response to 25 mM KCl in Ad-EGFP-transduced (n = 12) and Ad-EGFP-CaV3.1-transduced (n = 13) rat islets (Upper) and human islets (n = 9 for Ad-EGFP and n = 12 for Ad-EGFP-CaV3.1) (Lower). **P < 0.01 and *P < 0.05 vs. Ad-EGFP.
the cytosolic compartment to participate in the formation of \([Ca^{2+}]_i\). These \([Ca^{2+}]_i\) elevations might be associated with \(\beta\) cell function and play an important role in glucose intolerance during diabetes development (26–28). This prompted us to investigate the in vivo pathological role of Ad-EGFP-CaV3.1 transduction in diabetic rats. The impairment of first-phase glucose-stimulated insulin secretion represents the initial defect of \(\beta\) cell function and plays an important role in glucose intolerance during diabetes development (26–28). This prompted us to examine whether Ad-EGFP-CaV3.1 transduction altered \([Ca^{2+}]_i\) dynamics, leading to impaired glucose-stimulated insulin secretion. It turned out that both Ad-EGFP-CaV3.1-transduced rat and human islets showed significant elevations in \([Ca^{2+}]_i\) during perfusion with 3 mM glucose and stimulation with 16.7 mM glucose or 25 mM KCl compared to those treated with Ad-EGFP (Fig. 1 E and F). \([Ca^{2+}]_i\) curves registered from Ad-EGFP-CaV3.1-transduced islets were shifted upwards in comparison to those from islets transduced with Ad-EGFP (Fig. 1 E and F). These results substantiate the importance of the up-expressed CaV3.1 channels in rearranging \([Ca^{2+}]_i\) dynamics and thereby elevation in \([Ca^{2+}]_i\) in islets. However, intuitively, such an elevation in \([Ca^{2+}]_i\) should promote insulin secretion by allosterically triggering \(Ca^{2+}\)-dependent SNARE interactions (23–25). This suggests that elevated \([Ca^{2+}]_i\), in Ad-EGFP-CaV3.1-transduced islets may switch on other mechanisms to impair insulin secretion. Previous studies indicate the possibility that the elevation in basal \([Ca^{2+}]_i\), following Ad-EGFP-CaV3.1 transduction may activate CaN to dephosphorylate FoxO1, inducing its nuclear retention and down-regulation of some exocytotic proteins (17–19).

**Islets Transduced with Ad-EGFP-CaV3.1 Lose Their Ability to Normalize Hyperglycemia in Streptozotocin-Induced Diabetic Rats.** The impairment of first-phase glucose-stimulated insulin secretion represents the initial defect of \(\beta\) cell function and plays an important role in glucose intolerance during diabetes development (26–28). This prompted us to investigate the in vivo pathological role of Ad-EGFP-CaV3.1-transduced islets that exhibited defective basal insulin release and first-phase glucose-stimulated insulin secretion. We compared the abilities of control, Ad-EGFP-infected, and Ad-EGFP-CaV3.1-transduced islets to maintain basal insulin release and first-phase glucose-stimulated insulin secretion, as inferred from the area under the curve (AUC) of \([Ca^{2+}]_i\) dynamics, \(\beta\) cell insulin secretion, and \(\beta\) cell SNARE interactions (23–25). This suggests that elevated \([Ca^{2+}]_i\), in Ad-EGFP-CaV3.1-transduced islets may switch on other mechanisms to impair insulin secretion. Previous studies indicate the possibility that the elevation in basal \([Ca^{2+}]_i\), following Ad-EGFP-CaV3.1 transduction may activate CaN to dephosphorylate FoxO1, inducing its nuclear retention and down-regulation of some exocytotic proteins (17–19).
Fig. 3. Effects of Ad-EGFP-CaV3.1 transduction in combination with inhibition of CaV3.1 channels or calcineurin on p-FoxO1, FoxO1, syntaxin 1A, SNAP-25, and synaptotagmin III and VII levels. (A) Representative blots of cytoplasmic p-FoxO1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) bands in control INS-1E cells and cells transduced with Ad-EGFP, Ad-EGFP-CaV3.1, or Ad-EGFP-CaV3.1 in the presence of NNC55-0396. (B) Quantifications of p-FoxO1 immunoreactivity in the control group (n = 6) and groups transduced with Ad-EGFP (n = 6), Ad-EGFP-CaV3.1 (n = 6), and Ad-EGFP-CaV3.1 in the presence of NNC55-0396 (n = 6). **P < 0.01 vs. control and Ad-EGFP; *P < 0.05 vs. Ad-EGFP-CaV3.1 plus NNC55-0396. (C) Representative FoxO1 immunofluorescence (Left column), DAPI fluorescence (Middle column), and their overlay images (Right column) in Ad-EGFP-transduced INS-1E cells (Upper row) and Ad-EGFP-CaV3.1-transduced INS-1E cells in the absence (Middle row) and presence (Lower row) of NNC55-0396. Red and blue represent FoxO1 immunofluorescence and DAPI fluorescence, respectively. (Scale bars, 10 μm.) (D) Quantification of FoxO1 immunofluorescence in the Ad-EGFP (n = 9), Ad-EGFP-CaV3.1 (n = 10), and Ad-EGFP-CaV3.1 + NNC55-0396 (n = 8) groups. **P < 0.01 vs. Ad-EGFP and Ad-EGFP-CaV3.1 + NNC55-0396. FoxO1Fc, cytoplasmic FoxO1 immunofluorescence; FoxO1Fn, nuclear FoxO1 immunofluorescence. (E) Sample FoxO1 immunofluorescence (Left column), DAPI fluorescence (Middle column), and their overlay images (Right column) in Ad-EGFP-transduced INS-1E cells (Upper row) and Ad-EGFP-CaV3.1-transduced INS-1E cells without (Middle row) and with (Lower row) exposure to tacrolimus. Red and blue represent FoxO1 immunofluorescence and DAPI fluorescence, respectively. (Scale bars, 10 μm.) (F) Quantitative analysis of FoxO1 immunofluorescence in the Ad-EGFP (n = 9), Ad-EGFP-CaV3.1 (n = 12), and Ad-EGFP-CaV3.1 + tacrolimus (n = 9) groups. **P < 0.01 vs. Ad-EGFP and Ad-EGFP-CaV3.1 + tacrolimus. FoxO1Fc, cytoplasmic FoxO1 immunofluorescence; FoxO1Fn, nuclear FoxO1 immunofluorescence. (G) Representative blots of synaptotagmin III-, syntaxin 1A–, SNAP-25- and α-tubulin-immunoreactive bands in control islets and islets infected with Ad-EGFP or Ad-EGFP-CaV3.1. (H) Quantifications of synaptotagmin III, syntaxin 1A, and SNAP-25 immunoreactivities in the control (n = 5 for SNAP-25, n = 7 for syntaxin 1A, and n = 7 for synaptotagmin III), Ad-EGFP (n = 5 for SNAP-25, n = 7 for syntaxin 1A, and n = 7 for synaptotagmin III), and Ad-EGFP-CaV3.1 (n = 5 for SNAP-25, n = 7 for syntaxin 1A, and n = 7 for synaptotagmin III) groups. **P < 0.01 vs. control and Ad-EGFP. (I) Representative syntaxin 1A (stx1A, first column), SNAP-25 (second column), synaptotagmins III (sytIII, third column) and VII (sytVII, fourth column) immunofluorescence (red) overlaid with DAPI fluorescence (blue) in Ad-EGFP-transduced (Upper row) and Ad-EGFP-CaV3.1-transduced INS-1E cells untreated (Middle row) and treated (Lower row) with NCC55-0396. (Scale bars, 10 μm.) (J) Quantitative analysis of syntaxin 1A, SNAP-25, and synaptotagmin III and VII immunofluorescence in the Ad-EGFP (n = 14 for syntaxin 1A, n = 11 for SNAP-25, n = 11 for synaptotagmin III, and n = 14 for synaptotagmin VII), and Ad-EGFP-CaV3.1 + NNC55-0396 (n = 13 for syntaxin 1A, n = 11 for SNAP-25, n = 11 for synaptotagmin III, and n = 16 for synaptotagmin VII) groups. **P < 0.01 and *P < 0.05 vs. EGFP and Ad-EGFP-CaV3.1 + NNC55-0396. a.u., arbitrary units.
Ad-EGFP-Cav3.1-infected islets to ameliorate hyperglycemia in streptozotocin (STZ)-induced diabetic rats. These 3 groups of islets were transplanted into the anterior chamber of the eye of STZ-treated rats (Fig. 2A). All of them were well engrafted on the iris and richly vascularized within 4 wk after transplantation, during which both Ad-EGFP-Cav3.1- and Ad-EGFP-treated islets emitted appreciable EGFP fluorescence (Fig. 2B and C). STZ-treated rats manifested overt hyperglycemia before islet transplantation (Fig. 2D). Importantly, a significant normalization of hyperglycemia occurred in STZ-treated rats transplanted with either control islets or islets infected with Ad-EGFP but not in STZ-treated rats transplanted with Ad-EGFP-Cav3.1-transduced islets (Fig. 2D). Indeed, Ad-EGFP-Cav3.1-treated islets have no ability to ameliorate hyperglycemia in STZ-induced diabetic rats. Of note, no appreciable differences were found in the islet backscatter signal, which reflects functional islet cell mass (29), between control, Ad-EGFP-transduced, and Ad-EGFP-Cav3.1-transduced islets (Fig. 2C). This indicates that the enhanced expression of β cell Cav3.1 channels did not reach the extremely high level where these channels mediate exaggerated Ca\(^{2+}\) influx to cause Ca\(^{2+}\)-dependent islet cell damage, such as reduced insulin content, apoptosis, and necrosis.

**Transduction with Ad-EGFP-Cav3.1 Decreases Cytoplasmic p-FoxO1 and Induces FoxO1 Nuclear Retention through the Cav3.1 Channel-Dependent Activation of Calcineurin.** The unique ability of β cells to accurately release insulin in response to glucose critically relies on adequate expression of β cell–specific genes under the control of a defined set of transcription factors, including FoxO1 (18, 30, 31). This transcription factor acts not only downstream of complex Ca\(^{2+}\) signaling systems but also upstream of expression of β cell exocytotic proteins (18, 31). This made us question if elevated expression of Cav3.1 channels and resulting Ca\(^{2+}\) influx interfere with FoxO1 transcriptional action on β cell exocytotic protein genes with consequent impaired glucose-stimulated insulin secretion. We therefore quantified cytoplasmic phosphorylated FoxO1 in insulin-secreting INS-1E cells subjected to different treatments. It turned out that the relative abundance of cytoplasmic phosphorylated FoxO1 was significantly reduced in the Ad-EGFP-Cav3.1 group in comparison to that in the control and the Ad-EGFP groups as well as the group subjected to Ad-EGFP-Cav3.1 infection followed by exposure to the highly selective Cav3.1 channel blocker NNC55-0396 (Fig. 3A and B). All 4 groups exhibited similar intensities of GAPDH immunoreactivity (Fig. 3A). The reduction of cytoplasmic phosphorylated FoxO1 induced by elevated expression of Cav3.1 channels reflects decreased phosphorylation and increased retention of FoxO1 in the nucleus and suggests that the expression of β cell exocytotic protein genes downstream of FoxO1 is reduced.

To detect up-expressed Cav3.1 channel–induced changes in FoxO1 subcellular distribution and underlying mechanisms, we immunocytochemically characterized cytoplasmic and nuclear FoxO1 in INS-1E cells following Ad-EGFP-Cav3.1 transduction and treatment with NNC55-0396 or the Ca\(^{2+}\) Ni\(^{2+}\) inhibitor tacrolimus. Fig. 3C and E shows that FoxO1 immunofluorescence was more intense in the nuclei but less intense in the cytoplasm of cells transduced with Ad-EGFP-Cav3.1 than in those of Ad-EGFP-transduced cells. As shown in Fig. 3D and F, the ratio of nuclear to cytoplasmic FoxO1 in the Ad-EGFP-Cav3.1 group significantly increased compared to that in Ad-EGFP group. Importantly, the effects were effectively ablated by treatment with NNC55-0396 or tacrolimus (Fig. 3C–F). These results demonstrate that Ad-EGFP-Cav3.1 transduction indeed gives rise to FoxO1 nuclear retention through the Cav3.1 channel–dependent activation of CaN. They also suggest that the up-expressed Cav3.1-mediated Ca\(^{2+}\) influx is likely to constitutively hyperactivate CaN to make this phosphatase powerful enough to reach and dephosphorylate nuclear p-FoxO1, thereby preventing it from being extruded from the nucleus. In fact, the constitutively hyperactivated CaN has been demonstrated to dephosphorylate serine-256 of FoxO1 in ischemic neurons where [Ca\(^{2+}\)]\(_i\) is pathologically high (17, 32).

**Fig. 4.** Model depicting how elevated expression of β cell Cav3.1 channels impairs insulin release and glucose homeostasis. Unphosphorylated FoxO1 can bind to the promotor region of certain exocytotic protein genes to suppress their transcription. Under physiological conditions, however, the transcriptional suppression of FoxO1 hardly occurs since FoxO1 is phosphorylated and extruded from the nucleus to the cytoplasm. This ensures precise transcription of molecular and cellular events, including Cav channel–centered signaling systems but also upstream of expression of β cell exocytotic protein genes. The unique ability of β cells to accurately release insulin in response to glucose critically relies on adequate expression of β cell–specific genes under the control of a defined set of transcription factors, including FoxO1 (18, 30, 31). This transcription factor acts not only downstream of complex Ca\(^{2+}\) signaling systems but also upstream of expression of β cell exocytotic proteins (18, 31). This made us question if elevated expression of Cav3.1 channels and resulting Ca\(^{2+}\) influx interfere with FoxO1 transcriptional action on β cell exocytotic protein genes with consequent impaired glucose-stimulated insulin secretion. We therefore quantified cytoplasmic phosphorylated FoxO1 in insulin-secreting INS-1E cells subjected to different treatments. It turned out that the relative abundance of cytoplasmic phosphorylated FoxO1 was significantly reduced in the Ad-EGFP-Cav3.1 group in comparison to that in the control and the Ad-EGFP groups as well as the group subjected to Ad-EGFP-Cav3.1 infection followed by exposure to the highly selective Cav3.1 channel blocker NNC55-0396 (Fig. 3A and B). All 4 groups exhibited similar intensities of GAPDH immunoreactivity (Fig. 3A). The reduction of cytoplasmic phosphorylated FoxO1 induced by elevated expression of Cav3.1 channels reflects decreased phosphorylation and increased retention of FoxO1 in the nucleus and suggests that the expression of β cell exocytotic protein genes downstream of FoxO1 is reduced.

To detect up-expressed Cav3.1 channel–induced changes in FoxO1 subcellular distribution and underlying mechanisms, we immunocytochemically characterized cytoplasmic and nuclear FoxO1 in INS-1E cells following Ad-EGFP-Cav3.1 transduction and treatment with NNC55-0396 or the Ca\(^{2+}\) Ni\(^{2+}\) inhibitor tacrolimus. Fig. 3C and E shows that FoxO1 immunofluorescence was more intense in the nuclei but less intense in the cytoplasm of cells transduced with Ad-EGFP-Cav3.1 than in those of Ad-EGFP-transduced cells. As shown in Fig. 3D and F, the ratio of nuclear to cytoplasmic FoxO1 in the Ad-EGFP-Cav3.1 group significantly increased compared to that in Ad-EGFP group. Importantly, the effects were effectively ablated by treatment with NNC55-0396 or tacrolimus (Fig. 3C–F). These results demonstrate that Ad-EGFP-Cav3.1 transduction indeed gives rise to FoxO1 nuclear retention through the Cav3.1 channel–dependent activation of CaN. They also suggest that the up-expressed Cav3.1-mediated Ca\(^{2+}\) influx is likely to constitutively hyperactivate CaN to make this phosphatase powerful enough to reach and dephosphorylate nuclear p-FoxO1, thereby preventing it from being extruded from the nucleus. In fact, the constitutively hyperactivated CaN has been demonstrated to dephosphorylate serine-256 of FoxO1 in ischemic neurons where [Ca\(^{2+}\)]\(_i\) is pathologically high (17, 32).
molecular networks in β cells (6, 37, 38). De novo up-expression of β cell CaV3.1 channels plus pharmacological inhibition and characterization of the eventual ability of these genetically transduced islets to secrete insulin and normalize hyperglycemia enable us to dissect the role of elevated expression of β cell CaV3.1 channels in the development of diabetes from the aforementioned complexity. Furthermore, the combination of such approaches with analysis of the FoxO1 signaling pathway allowed us to identify a pathway from the up-expressed β cell CaV3.1 channels to transcriptional loci suppressing the expression of some exocytotic protein genes in the β cell. Limitations of the present work are due to the difficulty in obtaining islets from a large population of human donors with diabetes for experiments and recruiting sufficient numbers of patients with gain-of-function mutation of the CaV3.1 gene or epigenetic up-regulation of CaV3.1 gene expression for clinical trials. In this context, etiological heterogeneity in diabetes may hinder these basic and clinical studies since small sample sizes can bring about potential bias of experimental results (36). Our work suggests that enhanced expression of β cell CaV3.1 channels plays a causal role in pathogenesis of human diabetes. This remains to be verified by detailed clinical studies.

Conclusions
We demonstrated the feasibility of using Ad-EGFP-CaV3.1 to elevate CaV3.1 channel expression in islets. The elevated expression of CaV3.1 channels not only impairs both basal insulin release and first-phase glucose-stimulated insulin secretion with no influence on second-phase insulin response but also disables islets from normalizing hyperglycemia in STZ-induced diabetic rats. This happens since up-expressed CaV3.1 channels mediate excessive Ca2+ influx, resulting in pathological elevation of basal [Ca2+], which sequentially brings about activation of CaN, dephosphorylation, and nuclear retention of FoxO1 and FoxO1-mediated suppression of syntaxin 1A, SNAP-25, and synaptotagmin III gene transcription in the β cell (Fig. 4). Enhanced T-type Ca2+ currents through β cell CaV3.1 channels thus play a significant role in the development of a diabetic phenotype and suggest that β cell–specific blockade of these channels may be considered as an approach to treat diabetes.

Methods

Animals
Specific pathogen-free Wistar rats at 8 to 12 wk of age were obtained from Charles River Laboratories (Sulzfeld, Germany) and maintained on a regular light–dark cycle (lights on at 0700 and off at 1900) in temperature- and humidity-controlled rooms and had free access to food pellets and tap water. All animal experiments were conducted according to the guidelines of the Animal Care Committee of Karolinska Institute.

Additional experimental procedures are presented in the SI Appendix.

Data Availability
All of the data, associated protocols, and materials for this study are available within the paper and its SI Appendix.

ACKNOWLEDGMENTS
This work was supported by grants from Berth von Karwitz’s Foundation, Eurodia (FP6-518553), the ERC-2018-AdvG 834460 EYELETS, the Erling-Persson Family Foundation, Karolinska Institutet Funds, the Knut and Alice Wallenberg Foundation, National Natural Science Foundation of China (31500095), Skandia Insurance Company Ltd., the Stichting af Jochnick Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, Swedish Alzheimer’s Association, the Swedish Diabetes Association, Swedish Foundation for Strategic Research, the Swedish Research Council, and the Novo Nordisk Foundation. We thank Ms. Ingehild Ahshtedt at AstraZeneca for arranging human islets.